Q1 Earnings Estimate for Illumina Issued By Leerink Partnrs

Illumina, Inc. (NASDAQ:ILMN) – Leerink Partnrs increased their Q1 2025 EPS estimates for shares of Illumina in a research note issued on Tuesday, January 7th. Leerink Partnrs analyst P. Souda now expects that the life sciences company will earn $0.85 per share for the quarter, up from their prior estimate of $0.84. The consensus estimate for Illumina’s current full-year earnings is $4.11 per share.

A number of other equities analysts have also recently weighed in on the stock. Robert W. Baird increased their price objective on shares of Illumina from $124.00 to $139.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 6th. Citigroup cut shares of Illumina from a “buy” rating to a “neutral” rating and lowered their price objective for the stock from $190.00 to $165.00 in a research report on Wednesday, December 11th. HSBC raised shares of Illumina from a “hold” rating to a “buy” rating and set a $180.00 price objective for the company in a research report on Thursday, October 17th. Leerink Partners increased their price objective on shares of Illumina from $160.00 to $200.00 and gave the stock an “outperform” rating in a research report on Thursday, October 17th. Finally, Hsbc Global Res raised shares of Illumina from a “hold” rating to a “strong-buy” rating and set a $180.00 price target for the company in a research report on Thursday, October 17th. Eight investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $165.95.

Illumina Stock Performance

Illumina stock opened at $136.69 on Thursday. The firm has a 50 day simple moving average of $141.11 and a 200-day simple moving average of $132.27. Illumina has a 1-year low of $100.08 and a 1-year high of $156.66. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. The stock has a market cap of $21.68 billion, a price-to-earnings ratio of -13.72 and a beta of 1.11.

Illumina (NASDAQ:ILMN) last posted its quarterly earnings results on Monday, November 4th. The life sciences company reported $1.14 earnings per share for the quarter, beating the consensus estimate of $0.88 by $0.26. Illumina had a negative net margin of 36.10% and a positive return on equity of 7.29%. The business had revenue of $1.08 billion during the quarter, compared to analysts’ expectations of $1.08 billion. During the same quarter in the prior year, the company posted $0.33 EPS. The business’s revenue for the quarter was down 3.5% on a year-over-year basis.

Institutional Trading of Illumina

Several hedge funds and other institutional investors have recently made changes to their positions in the company. Empowered Funds LLC boosted its holdings in shares of Illumina by 1.7% in the third quarter. Empowered Funds LLC now owns 3,960 shares of the life sciences company’s stock valued at $516,000 after acquiring an additional 66 shares in the last quarter. Caprock Group LLC boosted its holdings in Illumina by 3.0% during the third quarter. Caprock Group LLC now owns 2,884 shares of the life sciences company’s stock worth $376,000 after buying an additional 83 shares in the last quarter. Integrated Advisors Network LLC boosted its holdings in Illumina by 2.0% during the third quarter. Integrated Advisors Network LLC now owns 4,484 shares of the life sciences company’s stock worth $585,000 after buying an additional 90 shares in the last quarter. Moors & Cabot Inc. boosted its holdings in Illumina by 1.7% during the third quarter. Moors & Cabot Inc. now owns 5,818 shares of the life sciences company’s stock worth $759,000 after buying an additional 95 shares in the last quarter. Finally, Carson Advisory Inc. boosted its holdings in Illumina by 3.8% during the third quarter. Carson Advisory Inc. now owns 2,757 shares of the life sciences company’s stock worth $360,000 after buying an additional 102 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.